-
SUPERNUS PHARMACEUTICALS, INC. v. TWI PHARMACEUTICALS, INC. et al DC CAFC
- 1:15-cv-00369
- D.N.J.
- Judge: Renee Marie Bumb
+1
- Filed: 01/16/2015
- Closed: 08/28/2017
- Latest Docket Entry: 12/02/2019
- PACER
1
Plaintiff
2
Defendants
1
Accused
Product
4
Patents-in-Suit
956
Days in
Litigation
-
SUPERNUS PHARMACEUTICALS, INC. v. TWI PHARMACEUTICALS, INC. et al DC CAFC
- 1:15-cv-00369
- D.N.J.
- Judge: Renee Marie Bumb
+1
- Filed: 01/16/2015
- Closed: 08/28/2017
- Latest Docket Entry: 12/02/2019
- PACER
Cause of Action
Willful Patent Infringement
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method of treating seizures comprising administering to a subject in need thereof a pharmaceutical formulation comprising a homogeneous matrix comprising: (a) oxcarbazepine; (b) a matrix-forming polymer selected from the group consisting of
view more
|
Valid
Entry 339 Entry 361 |
| 11 |
The method of claim 10, wherein the formulation is in the form of tablets.
|
Valid
Entry 339 Entry 361 |
| 21 |
The method of claim 1, wherein the formulation is administered once a day.
|
Valid
Entry 339 Entry 361 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A pharmaceutical formulation for once-a-day administration of oxcarbazepine comprising a homogeneous matrix comprising: (a) oxcarbazepine; (b) a matrix-forming polymer selected from the group consisting of cellulosic polymers, alginates, gums,
view more
|
Valid
Entry 339 Entry 361 |
| 11 |
The formulation of claim 10 in the form of tablets.
|
Valid
Entry 339 Entry 361 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A pharmaceutical formulation for once-a-day administration of oxcarbazepine comprising a homogeneous matrix comprising: (a) oxcarbazepine; (b) 1-50%, by weight of the formulation, a matrix-forming polymer; (c) 1-80%, by weight of the formulation, at
view more
|
Valid
Entry 339 Entry 361 |
| 19 |
The formulation of claim 18, in the form of tablets.
|
Valid
Entry 339 Entry 361 |
-
Infringement
TWI International LLC
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 150 mg, 300 mg, 600 mg of oxcarbazepine extended-release tablets pursuant to ANDA No. 206576Generic version of Oxtellar XR | US 7,722,898 B2 |
1, 11
|
Infringement
Entry 339Entry 361 |
| Generic 150 mg, 300 mg, 600 mg of oxcarbazepine extended-release tablets pursuant to ANDA No. 206576Generic version of Oxtellar XR | US 7,910,131 B2 |
1, 11, 21
|
Infringement
Entry 339Entry 361 |
| Generic 150 mg, 300 mg, 600 mg of oxcarbazepine extended-release tablets pursuant to ANDA No. 206576Generic version of Oxtellar XR | US 8,821,930 B2 |
1, 19
|
Infringement
Entry 339Entry 361 |
TWI Pharmaceuticals Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 150 mg, 300 mg, 600 mg of oxcarbazepine extended-release tablets pursuant to ANDA No. 206576Generic version of Oxtellar XR | US 7,722,898 B2 |
1, 11
|
Infringement
Entry 339Entry 361 |
| Generic 150 mg, 300 mg, 600 mg of oxcarbazepine extended-release tablets pursuant to ANDA No. 206576Generic version of Oxtellar XR | US 7,910,131 B2 |
1, 11, 21
|
Infringement
Entry 339Entry 361 |
| Generic 150 mg, 300 mg, 600 mg of oxcarbazepine extended-release tablets pursuant to ANDA No. 206576Generic version of Oxtellar XR | US 8,821,930 B2 |
1, 19
|
Infringement
Entry 339Entry 361 |